Table 2.
Comparison of Imaging Features of Patients Between TR and TN Groups
| Characteristics | TR | TN | P |
|---|---|---|---|
| N=31 | N=79 | ||
| Diameter | 8.23 [1.33–19.01] | 11.35 [4.52–28.1] | 0.001 |
| Tumor number | 0.012 | ||
| 1 | 18 (0.58) | 26 (0.33) | |
| 2 | 5 (0.16) | 18 (0.23) | |
| 3 | 3 (0.1) | 5 (0.06) | |
| >3 | 5 (0.16) | 30 (0.38) | |
| Distribution | 0.006 | ||
| One segment | 7 (0.23) | 3 (0.04) | |
| One lobe | 15 (0.48) | 35 (0.44) | |
| Multiple lobe | 9 (0.29) | 35 (0.44) | |
| Portal thrombosis | 4 (0.13) | 44 (0.56) | <0.001 |
| Grade I | 1 (0.03) | 6 (0.08) | |
| Grade II | 1 (0.03) | 17 (0.22) | |
| Grade III | 2 (0.06) | 17 (0.22) | |
| Grade IV | 0 | 4 (0.05) | |
| Venous thrombosis | 1 (0.03) | 12 (0.15) | 0.023 |
| Biliary invasion | 1 (0.03) | 2 (0.03) | 0.851 |
| Infiltrated growth | 1 (0.03) | 15 (0.19) | 0.005 |
| Tumor vessels | 19 (0.61) | 65 (0.82) | 0.039 |
| Peritumor enhancement | 10 (0.32) | 44 (0.56) | 0.026 |
| Arterial hyperenhancement | 22 (0.71) | 56 (0.71) | 0.993 |
| CTN (HU) | 43.37 [31–55.6] | 43.53 [26.1–58.7] | 0.914 |
| CTA (HU) | 89.3 [46.6–150] | 87.91 [38.5–152] | 0.787 |
| CTV (HU) | 87.8 [50.1–119.3] | 86.8 [55.2–127.2] | 0.770 |
| ΔA (HU) | 45.94 [2.7–98.9] | 44.39 [8.6–103.7] | 0.742 |
| ΔA% | 1.06 [0.06–1.97] | 1.04 [0.16–2.26] | 0.861 |
| Tumor capsule | 21 (0.68) | 53 (0.67) | 0.948 |
| Necrosis | 22 (0.71) | 71 (0.9) | 0.041 |
| Splenomegaly | 14 (0.45) | 39 (0.49) | 0.696 |
Abbreviations: ΔA, increased CT value on arterial phase; ΔA%, increased ratio of CT value on arterial phase; CTA, CT values of tumor parenchyma measure on arterial phase; CTN, CT values of tumor parenchyma measure on plain scan; CTV, CT values of tumor parenchyma measure on portal vein phase; TN, nonresponsive to transarterial chemoembolization (TACE); TR, responsive to TACE.